---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-148920"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:45:34.348773+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics appoints Eric J. Daniels as CDO; base salary $460K, equity grant

## Summary
- Daniels becomes Chief Development Officer effective April 20, 2026, reporting to CEO.
- Prior role: Chief Development Officer at Kiora Pharmaceuticals (NASDAQ:KPRX) from Oct 2021 to Apr 2026.
- Initial annual base salary of $460,000; target bonus of 40% of base salary.
- Equity inducement: option for 20,000 shares vesting over 4 years (1-yr cliff) and 20,000 RSUs vesting over 3 years.
- Severance on involuntary termination: 12 months' salary plus target bonus, plus vesting acceleration on 9 months of unvested equity.

## SEC filing metadata
- accession: 0001193125-26-148920
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/0001193125-26-148920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/pstv-20260408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-148920
- JSON: https://secwatch.observer/filing/0001193125-26-148920.json
- Plain text: https://secwatch.observer/filing/0001193125-26-148920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.